News and Press Releases
TECVAYLI▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing Separate analyses from the MajesTEC-1 and OPTec...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brain
The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
DARZALEX (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma
88% of transplant-eligible patients achieved a complete response or better, and 47% of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous formulation-based regimens in the phase 3...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Lykos Therapeutics Appoints Finance Veteran Scott Giacobello to the Board of Directors
30 May 2024 -- California, US -- Lykos Therapeutics, a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective immediately. A...
Category: Biotechnology, Clinical Trials, Other
Posted: May 30, 2024
Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
SOD1-ALS is a devastating, uniformly fatal and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe QALSODY is Biogen’s third rare disease therapy to be...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 30, 2024
Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease
Builds on preclinical proof-of-concept that MTX325 protects dopamine-producing brain cells by enhancing mitophagy – the process cells use to remove dysfunctional mitochondria 21 March 2024 -- Cambridge, UK -- Mission...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 21, 2024
Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom
Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic
Proof-of-concept study to investigate personalised dose management of first-line anti-hypertensive in improving blood pressure control remotely Key milestone in co-development partnership to combine leading medicine brands with dose optimisation technology...
Category: Biotechnology, Clinical Trials
Posted: May 16, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
Greenphire Named 2024 “Best Overall Patient Engagement Service” by MedTech Breakthrough Awards
16 May 2024 -- Pennsylvania, US -- Greenphire, a leading innovator in software solutions for improving clinical research site performance and participant satisfaction, has received a 2024 MedTech Breakthrough Award for...
Category: Clinical Trials, Logistics
Posted: May 16, 2024
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
Safety of ALX-001 reinforced by new data presented at AD/PD 2024 Conference in Lisbon, Portugal Two oral doses selected for further study in Alzheimer’s and Parkinson’s disease patients. 11 March 2024...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 11, 2024
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at Six Weeks
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing phase 1/2...
Category: Biotechnology, Clinical Trials
Posted: May 8, 2024
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG
Signant Health extends eCOA leadership position through operational innovations that reduce timelines by at least one-third
8 May 2024 -- Pennsylvania, US -- Signant Health, the leader in evidence generation for modern clinical trials, announced today that it has substantially reduced implementation timelines for its flagship...
Category: Clinical Trials, Other
Posted: May 8, 2024
Phesi launches predictive Patient Burden Score to improve trial efficiency, patient experience and investigator site performance
Latest real-world metric in Phesi’s AI-driven Trial Accelerator quantifies patient burden to unlock a patient-centric approach to trial design and implementation 7 May 2024 -- Boston, US -- Phesi, a...
Category: Clinical Trials
Posted: May 7, 2024
Broken String Biosciences and the Francis Crick Institute collaborate to advance ALS research
Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis 07 May 2024 -- Cambridge and London,...
Category: Drug Discovery, Pharmaceutical
Posted: May 7, 2024
Unit AB3-04, Level 3 BioData Innovation Centre Wellcome Genome Campus Hinxton Cambridge, CB10 1DR
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations 5 May 2024 -- Beerse, Belgium -- Janssen-Cilag International,...
Category: Clinical Trials, Drug Discovery
Posted: May 5, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Bespak and Medicines Evaluation Unit collaborate to accelerate clinical trials on climate-friendly inhalers
Relationship will provide pharmaceutical industry with fast route to clinical evaluation of low GWP pMDIs 3 May 2024 -- Holmes Chapel and Manchester, UK -- Bespak, a leading contract development...
Category: Clinical Trials, Drug Delivery
Posted: May 3, 2024
